Aspen Announces The Acquisition Of A Portfolio Of Products In Latin America From Viatris
Aspen Announces The Acquisition Of A Portfolio Of Products In Latin America From Viatris. Aspen is pleased to announce that Aspen Global Incorporated (“AGI”), its wholly owned subsidiary incorporated in Mauritius, has on 31 July 2023 concluded an agreement in terms of which it will acquire from Viatris Inc. (“Viatris”) the commercialisation rights and related intellectual property for a portfolio of well- known branded products in Latin America.
The fair value of the Products has been determined by AGI as USD 280 million. AGI will settle the resultant consideration due by means of a combination of a cash payment of USD 150 million and an extension of supply terms to Viatris. Viatris is a major global pharmaceutical company, publicly listed on the New York NASDAQ and with principal offices in Canonsburg, Pennsylvania, United States of America.
The transaction represents an attractive opportunity for Aspen to expand its presence in one of the Group’s key regions. In doing so, Aspen will acquire a basket of well established, post-patent brands that will complement its existing portfolio and add to the scale of its business in this region. Furthermore, the acquisition of a dedicated and experienced sales team will materially enhance Aspen’s commercial capabilities, further strengthening its foundations for future growth in Latin America.
With a 170-year heritage, Aspen is a global specialty and branded multinational pharmaceutical company with a presence in both emerging and developed markets. The company has approximately 9 100 employees at 69 established offices in over 50 countries as it aims to improve the health of patients in more than 150 countries through its high quality, affordable medicines.
Aspen focuses on marketing and manufacturing a broad range of post-patent, branded medicines and domestic brands covering both hospital and consumer markets through its key business segments. The company’s key business segments are Manufacturing and Commercial Pharmaceuticals comprising Regional Brands and Sterile Focus Brands.
